MemoDero

Company Overview

Snapshot

Founded in January 2015 by Raphael Lamprecht, MemoDero operated with 1–10 employees. The company focused on developing a drug candidate to prevent fear-related disorders, a technology that was recognized for its potential in pharmaceutical development.

Business overview

MemoDero was a Health Tech & Life Sciences company specializing in the development of a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases, such as post-traumatic stress disorder (PTSD). The company's core technology involved the drug pep-EphrinA4, aimed at inhibiting the development of fear memory following traumatic events. MemoDero operated within the Pharmaceuticals & Diagnostics sector, targeting the broader healthcare and life sciences market.

Company Intelligence Q&A

What was MemoDero's primary focus?

MemoDero focused on developing a first-in-class drug candidate designed to prevent the debilitating consequences of fear-related diseases, including post-traumatic stress disorder (PTSD).

When was MemoDero founded?

MemoDero was founded in January 2015.

Who was a key founder of MemoDero?

Professor Raphael Lamprecht was a scientific founder of MemoDero.

What was the status of MemoDero?

MemoDero ceased to operate in February 2022.

What was the name of the drug candidate MemoDero was developing?

MemoDero was in advanced stages of developing and evaluating the drug pep-EphrinA4.